DIRS.INFO The most relevant business & tech news

☆ Oprah Winfrey apologizes for being 'major contributor' to shaming diet culture and the 'wagon of fat' moment
▼ + stars: | 2024-05-11 | by ( Eve Crosbie | ) www.businessinsider.com time to read: +4 min

"I've been a steadfast participant in this diet culture. AdvertisementIn 1988, Oprah Winfrey appeared on her show pulling a wagon full of fat, representing the 67 pounds she had lost in four months. Now, Winfrey told the audience that she wants to support them in their shift toward self-acceptance and healthier mindsets. Oprah Winfrey discussed her history with weight loss culture during the three-hour live stream from Weight Watchers. Shortly after, the Oscar winner helmed the ABC televised special "Shame, Blame and the Weight Loss Revolution," which saw her discuss the growing popularity of weight loss drugs such as Ozempic, Mounjaro, and Wegovy.

Persons: —, Oprah Winfrey, Winfrey, I've, makeovers, We've, Sima Sistani Organizations: Service, Business, WW International, National Museum of, WeightWatchers, ABC

☆ Oprah Winfrey: I set an unrealistic standard for dieting
▼ + stars: | 2024-05-09 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +4 min

New York CNN —Oprah Winfrey said on Thursday evening that she has long played a role in promoting unhealthy and unrealistic diets. I cannot tell you how many weight loss shows and makeovers I have done and they have been a staple since I’ve been working in television,” she said. Winfrey told People Magazine in December that she has added a “weight-loss medication to her regimen” but didn’t specify which drug. Winfrey and WeightWatchersWinfrey left the board of WeightWatchers, ending a nearly decade-long stint as a director of the beleaguered company, in February. “I will say that I was on the board at the time there were discussions about whether or not WeightWatchers would move into weight loss medications,” Winfrey said on Thursday.

Persons: Oprah Winfrey, ”, I’ve, makeovers, Winfrey, Rebel Wilson, Amber Riley, Sima Sistani, Sistani, WeightWatchers Winfrey, ” Winfrey, Oprah, WeightWatchers, ” WeightWatchers, Jimmy Kimmel, “ Organizations: New, New York CNN, YouTube, WeightWatchers, Magazine, National Museum of, Goldman Sachs Locations: New York

☆ WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit
▼ + stars: | 2024-03-14 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

But since then WW shares have suffered heavy selling, dropping to a new 52-week low on Thursday. The stock, due to its debt load and short interest, as well as the general anxiety about the impact of the new weight loss drugs, is subject to heightened volatility. In the memo, Sistani told employees she wanted "to take a moment to address some of the breathless media coverage." WW shares closed at $1.87 on Thursday. It noted that WW was among companies from the weight loss industry involved in the TV event.

Persons: Oprah Winfrey, Sistani, Eli Lilly, Sima Sistani, Guggenheim, Oprah, Winfrey Organizations: CNBC, Nordisk, Guggenheim Partners, Guggenheim, WeightWatchers Clinic, FDA, WeightWatchers, National Museum of, ABC

☆ Oprah is leaving WeightWatchers’ board, sending stock tumbling 25%
▼ + stars: | 2024-02-29 | by ( Jordan Valinsky | ) edition.cnn.com time to read: +2 min

New York CNN —Oprah Winfrey is leaving the board of WeightWatchers, ending a nearly decade-long stint as a director of the beleaguered company that has faced sudden competition from Ozempic. WeightWatchers shares (WW) plunged 25% in premarket trading Thursday and would be down 85% for the past six months if the premarket losses hold. WeightWatchers has faced more competition recently from GLP-1 prescriptions drugs like Ozempic and Wegovy sometimes used for weight loss. Last year, WeightWatchers also made a $100 million-plus deal to buy Sequence, a telehealth business that offers virtual prescriptions to patients for these weight loss drugs where appropriate. Winfrey told People Magazine in December that she has added a “weight-loss medication to her regimen” but didn’t specify which drug.

Persons: Oprah Winfrey, Winfrey, ”, Oprah, Sima Sistani, WeightWatchers, ” Winfrey Organizations: New, New York CNN, Ozempic, National Museum of, WeightWatchers, Magazine Locations: New York, GLP

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ How to access the new weight loss drugs
▼ + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com time to read: +7 min

(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.

Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”

☆ 3 titans will fight to dominate the market for Wegovy in 2024
▼ + stars: | 2023-12-27 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Dozens of startups have jumped into the weight-loss market this year as weight-loss drugs, including Wegovy and Ozempic, have exploded in popularity. The few companies with enough money and brand recognition to stand up to Ozempic's distribution challenges — WeightWatchers, Noom, and Ro — can expect to compete for market dominance next year. But WeightWatchers signaled it's going all in on weight-loss drugs by launching its own behavioral program for patients on Ozempic in December. WeightWatchersLike WeightWatchers, Noom has remained staunchly in the weight-loss market since its 2008 launch. Ro launched its own program prescribing weight-loss drugs in January.

Persons: VCs, — WeightWatchers, Sari Kaganoff, WeightWatchers, it's, Sima Sistani, Noom, Ro, Zach Reitano, Kaganoff, Saeju Jeong, Sam Barnes, Aaron DeGagne Organizations: Business, Rock Health, Web, Getty, PitchBook Locations: Ozempic

☆ Sima Sistani says its time for WeightWatchers to embrace Ozempic. Will its users agree?
▼ + stars: | 2023-11-28 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +10 min

Sima Sistani, the 44-year-old CEO of WeightWatchers, is aware of this, and she recognized WeightWatchers had to evolve – or else. She also landed a massive deal to buy a telehealth business that can issue virtual prescriptions to patients for these weight loss drugs. Semaglutide was approved by the US Food and Drug Administration to treat type 2 diabetes as Ozempic, but it was also used off-label for weight loss. Some longtime users of the program feel betrayed by the pivot away from in-person meetings and toward medication-based solutions. “Sadly, they don’t want to do the work,” she said, of tracking food or exercising to achieve weight loss goals.

Persons: New York CNN —, Sima Sistani, WeightWatchers, she’s, Sistani, “, ” Sistani, Erica Shroeder, ”, Jaap Arriens, ” Goldman Sachs, Jenny Craig, Adam Rockmore, Ged, Angela Weiss, Variety Sistani, there’s, Semaglutide, aren’t, “ there’s, Oprah Winfrey, Jamie Yonash, influencers, Velanti, Michael Nagle, We’re Organizations: New, New York CNN, Walmart, CNN, WeightWatchers, Variety, US Food and Drug Administration, Bloomberg, Getty Locations: New York, Cola, Wegovy

☆ The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it's a top pick
▼ + stars: | 2023-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

Sequence gives subscribers access to GLP-1 medications such as Novo Nordisk's Wegovy and Ozempic. Schenk said the concern about the drop in WW's average revenue per user "seems overblown" and has created a buying opportunity for the stock. Stabilizing core business WW has been focused on stabilizing its core weight loss business. Both developments are a positive for WW's Sequence business. Schenk estimates that around 6 million current or lapsed WW subscribers would qualify for treatment with obesity medication.

Persons: Sima Sistani, Morgan Stanley, Lauren Schenk, Eli Lilly, Schenk, Lilly, Novo Organizations: International, Nordisk's Wegovy, FDA, 3Q, and Drug Administration, Novo Nordisk Locations: Friday's, Novo

☆ The Company That Defined Dieting Is Sorry It Told Us to Have More Willpower
▼ + stars: | 2023-10-07 | by ( Erich Schwartzel | ) www.wsj.com time to read: 1 min

WeightWatchers Chief Executive Sima Sistani hears from them all of the time, those customers she thinks her company has failed. They fill her Instagram inbox with messages detailing their years on the WeightWatchers count-your-points program, a frustrating pattern of fluctuating weight that only made them feel like they weren’t trying hard enough.

Persons: Sima Sistani

☆ This is the first time in WW history that Q2 ended higher than Q1, says CEO Sima Sistani
▼ + stars: | 2023-08-16 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThis is the first time in WW history that Q2 ended higher than Q1, says CEO Sima SistaniSima Sistani, WW International CEO, joins 'Closing Bell Overtime' to talk weight loss drugs, growth in WW's digital platforms and the stock's reaction.

Persons: Sima Sistani Sima Sistani Organizations: WW International

☆ WeightWatchers could either win big or lose faithful customers, or both, in its pivot to Ozempic trend
▼ + stars: | 2023-07-22 | by ( Jordan Hart | ) www.businessinsider.com time to read: +3 min

Sequence offers access to weight-loss drugs like Ozempic and Wegovy. Analysts say the move could save the company, but some WeightWatchers members aren't happy. Although the medication has gained popularity online and among celebrities, veteran WeightWatchers members aren't all happy with the company's pivot. Some WeightWatchers members expressed concern that the company was abandoning its message of self-restraint for the easy solution of weight-loss medication. Sequence, meanwhile, prescribes weight-loss medications like Ozempic and Wegovy and helps patients afford the drugs through insurance and reimbursements.

Persons: WeightWatchers, aren't, They're, Goldman Sachs, Sima Sistani, Jenny Craig Organizations: WW, Inc, Bloomberg, Employers

☆ WW International CEO on weight loss drugs: Still critical you make the right lifestyle changes
▼ + stars: | 2023-03-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWW International CEO on weight loss drugs: Still critical you make the right lifestyle changesCNBC's Meg Tirrell talks with Sima Sistani, WW International CEO, on 'Closing Bell: Overtime' to discuss the company's stock surge after announcing it had acquired Sequence, a telehealth platform that helps treat obesity.

☆ WeightWatchers stock surges 70% after company agrees to buy obesity treatment platform
▼ + stars: | 2023-03-07 | by ( Rebecca Picciotto | ) www.cnbc.com time to read: +1 min

Shares of WW International , also known as WeightWatchers, skyrocketed Tuesday after the company said it planned to buy Sequence, a telehealth platform that provides treatment for obesity. Shares of the company were down 57% over the past year as it struggled to pivot to wellness and move away from weight loss. Sistani took over as chief executive at the end of February, steering the company back toward weight loss messaging. The Sequence announcement comes as companies across the weight loss industry look to offer obesity medications as a pathway to customers looking to shed pounds. The trend has led to a shortage in medications like Ozempic, which are commonly prescribed for Type 2 diabetes.

☆ WeightWatchers is buying a company that lets you pay $99 a month to see a doctor on video and get a prescription to popular weight-loss drug Ozempic
▼ + stars: | 2023-03-07 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +4 min

WeightWatchers announced Monday it was buying Sequence, a clinical weight management platform. Members will get Sequence's services including telehealth visits and prescriptions for weight loss drugs like Ozempic. Through Sequence's $99-a-month subscription program, customers can schedule telehealth appointments with doctors who will prescribe weight loss and diabetes management drugs like Ozempic and Wegovy. "As science advances rapidly, we know there is a significant opportunity to improve outcomes for those using medications," WeightWatchers' CEO Sima Sistani said in a press release. Doctors are even adding the hashtags to videos that are about weight loss solutions that don't rely on those medications.

☆ Under threat, Weight Watchers enters obesity drug space. Here's what it means for the stock
▼ + stars: | 2023-03-07 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

The company's sales have been in a steady multiyear decline after an attempt to de-emphasize weight loss and focus on wellness failed miserably. WW 1Y mountain The parent of Weight Watchers has seen its market value shrink as sales have dropped for several years. Another drug, Eli Lilly's Mounjaro, adds a second incretin hormone to the mix and has been shown to be even more successful with weight loss. This trend could provide an opportunity for the core Weight Watchers brand and its focus on behavior modification. That scenario assumes Weight Watchers continues to see membership erosion, while cost controls help minimize margin compression.

☆ A generation of high-profile women tech leaders have stepped aside. What’s next?
▼ + stars: | 2023-02-24 | by ( Catherine Thorbecke | ) edition.cnn.com time to read: +7 min

The tech industry has now lost an entire generation of trailblazing women leaders and replaced them mostly with men. And in the wake of the pandemic, women leaders in corporate America more broadly are more likely than ever to quit, according to the most recent Women in the Workplace report from McKinsey & Company and LeanIn.Org. Now that she’s departing, Big Tech is facing a new reckoning over its failure to promote and support women leaders, and what this could mean for the next generation of women in the industry. “Without women in the C-suite who have come before them, it could make this transition period tougher for next generation women leaders,” Kray said. “I think that what she achieved and what she modeled will be something that will live on beyond the fact that now we don’t have a female Big Tech CEO.”

Search resuls for: "Sima Sistani"

17 mentions found